首页> 外文会议>Annual International Conference of the IEEE Engineering in Medicine and Biology Society >Therapeutic effects of anti-spastic medication on neuromuscular abnormalities in SCI: A system identification approach
【24h】

Therapeutic effects of anti-spastic medication on neuromuscular abnormalities in SCI: A system identification approach

机译:抗痉挛药物对SCI神经肌肉异常的疗效:一种系统识别方法

获取原文

摘要

Previous attempts to investigate the effects of antispastic medications are limited to clinical studies using that use clinical evaluations to assess. Since these measures are neither objective nor quantitative, the therapeutic effects of such medications on neuromuscular properties have not been fully evaluated. In this study, as a first attempt, we examined the effect of tizanidine, an anti-spastic medication, on modification of the neuromuscular properties of patients with chronic incomplete spinal cord injury (SCI). Each patient was administered 2 mg of tizanidine four times per day for four weeks. The spastic ankle of each patient was evaluated at baseline (prior to any medication, and then 1, 2, and 4 weeks after the start of medication. The ankle was perturbed with a small-amplitude Pseudo-Random Binary Sequence (PRBS) perturbation at various positions over the ankle range-of-motion. A parallel-cascade system identification technique, which provides an objective and quantitative measure of neuromuscular properties, was used to calculate the intrinsic and reflex stiffness. The stiffness vs. joint angle trends were then calculated for each evaluation; these curves were compared across the intervention time to determine the recovery pattern (i.e. change over time) due to the tizanidine intervention. All patients exhibited decreases in reflex stiffness (which abnormally increase after SCI) due to the medication; however, patients were observed to exhibit multiple recovery patterns. For some patients, the reflex stiffness continuously reduced over the four-week intervention period, while for other patients, the decrease during the first week (i.e. between the baseline and 1-Week evaluations) was most pronounced. Also, some patients presented a significant decrease with time, while others presented no improvement in the intrinsic stiffness. These findings suggest that tizanidine may be effective in reducing not only reflex stiffness, but also the subject's intrin- ic stiffness for certain patients. Future work remains to identify predictors which can objectively determine which patients are likely to exhibit maximal benefit from the tizanidine prior to being prescribed with the medication.
机译:以前试图探讨抗爆药物的影响仅限于使用使用临床评估来评估的临床研究。由于这些措施既不是客观也不定量,因此此类药物对神经肌肉性能的治疗效果尚未得到完全评估。在这项研究中,作为第一次尝试,我们研究了钛尼丁,抗痉挛药物,抗痉挛药物的效果对慢性不完全脊髓损伤(SCI)的患者神经肌肉特性的改变。每只患者每天4次施用2毫克钛氨酸四周。每位患者的痉挛脚踝在基线(在任何药物之前,然后在药物开始后1,2和4周)评估。踝部扰动了小幅度伪随机二进制序列(PRB)扰动在踝关节运动范围内的各种位置。采用平行级联系统识别技术,其提供了一种物理和定量的神经肌肉特性测量,用于计算内在和反射刚度。然后计算刚度与关节角度趋势对于每个评估;通过替苏丹干预,在干预时间进行比较这些曲线,以确定由于替苏丁干预而确定恢复模式(即随时间的变化)。由于药物治疗,所有患者表现出反射刚度(SCI异常增加)降低;然而,观察患者表现出多种恢复模式。对于一些患者,反射僵硬在四周干预期间持续减少,对于其他患者,第一周的减少(即在基线和1周的评估之间最明显。此外,一些患者随着时间的推移提出了显着的减少,而其他患者则没有提高内在刚度。这些研究结果表明,钛尼汀可能有效地减少反射僵硬,而且还有某些患者的受试者的内部IC刚度。未来的工作仍然识别预测因子,这些预测因子可以客观地确定哪些患者在用药方案之前从钛烷中表现出最大益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号